- Demand for erectile dysfunction drugs has been strong in the recent past. Lifestyle diseases such as hypertension, diabetes, etc. are a major reason for erectile dysfunction. Stress and sedentary lifestyles are triggering the onset of lifestyle diseases. Medications for treating these conditions also cause erectile dysfunction.
For Market Research Report on “Erectile Dysfunction Drugs Market” Visit -http://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market
Awareness regarding erectile dysfunction and drugs for treating it has augmented due to various factors. This has fueled demand for the market. The erectile dysfunction drugs market was worth about USD 5 billion in 2014. It could benefit from governmental reforms and awareness campaigns in Asia Pacific and Latin America.
Other favorable factors for the market include improving healthcare infrastructure, economic development, and growing target population. Medical innovations such as new molecule combinations and drug delivery techniques (creams, pellets, etc) present future opportunities. These trends assure higher drug efficacy and performance.
Despite the aforesaid drivers, the market will witness a downfall over the forecast period (2015 to 2022). By 2022, it would be valued only around USD 3 billion. This could be attributed to forthcoming expiration of leading drug patents. Other inhibitors of the erectile dysfunction drugs market comprise threat from counterfeit products, narrowing insurance coverage, bigger risk of sexually transmitted diseases, and social stigma in developing regions.
The market is segregated into products and regions. Some of the product segments encompass Viagra (sildenafil citrate), Zydena (udenafil), and Cialis (tadalafil). Stendra/Spedra (avanafil), Vitaros (alprostadil cream), Levitra/Staxyn (vardenafil), and others are the rest. Viagra is the most-demanded product. It accounted for close to 48% of the global revenues in 2014 and is often the first line of treatment.
Viagra’s dominance is challenged by Cialis and Levitra. Its patent would expire in the U.S. in 2019. Yet, Viagra is estimated to control 30% of the erectile dysfunction drugs market by 2022. This is due to its strong brand identity and customer loyalty. Zydena, Stendra/Spedra, and Vitaros would grab greater shares after Cialis and Levitra patents expire in 2017 and 2018, respectively.
Regional segments comprise North America, Asia Pacific, Europe, and Rest of the World (RoW). North America led the market in 2014, while Europe was placed second. The former benefits from well-established healthcare systems, huge demand, and extensive medical research. Asia Pacific is anticipated to grow at a CAGR of 2.5% during the forecast period.
Key competitors in the global erectile dysfunction drugs market are Bayer AG, Pfizer Inc., Eli Lily and Company, and Apricus Biosciences Inc. The time period post expiry of patents can be marked by mergers, acquisitions, & collaborations.
Information Source: Grand View Research
To request a sample copy of this report, please complete the form below.
To purchase a copy of this report, please contact at
28 2nd Street, Suite 3036
San Francisco, CA 94105
Toll Free: 1-888-202-9519